New eye drug aims to slow vision loss in dry AMD
NCT ID NCT06087458
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This early-stage trial is testing a new drug called VOY-101 in 60 people with advanced dry age-related macular degeneration (AMD), a leading cause of vision loss. The drug is injected into the eye and aims to slow the growth of damaged areas (geographic atrophy) and preserve retinal health. The study will first test different doses for safety, then look at how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cerulea Clinical Trials
ACTIVE_NOT_RECRUITINGEast Melbourne, Victoria, 3002, Australia
-
Rambam Medical Center
RECRUITINGHaifa, Israel
-
Retina Center of Texas
RECRUITINGSouthlake, Texas, 76092, United States
-
Retina Consultants San Diego
RECRUITINGSan Diego, California, 92064, United States
-
Retina Macula Institute of AZ
RECRUITINGScottsdale, Arizona, 85255, United States
-
Retinal Consultants Medical Group
RECRUITINGSacramento, California, 95825, United States
-
Star Retina
RECRUITINGBurleson, Texas, 76028, United States
-
Sydney Retina Clinic and Day Surgery
ACTIVE_NOT_RECRUITINGSydney, New South Wales, 2000, Australia
-
Tel-Aviv Sourasky Medical Center, Ophthalmology Division
RECRUITINGTel Aviv, 64239, Israel
-
The Retina Partners
RECRUITINGEncino, California, 91436, United States
-
University of Utah John A. Moran Eye Center
RECRUITINGSalt Lake City, Utah, 84132, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VOY-101 (a biologic drug injected into the eye)
What this could lead to
If it works, this could slow the progression of advanced dry AMD and help preserve vision for longer.
What could go wrong
This is an early-phase trial with only 60 people, so it may not work as hoped. There are also risks from the eye injection, such as infection or inflammation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.